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Abstract
Background: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in
their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the
use of typical and atypical antipsychotic drugs in the Israeli inpatient psychiatric population throughout the last decade.
Methods: Data regarding allocation of typical and atypical antipsychotics, over the period 2004 to 2013, were extracted
from the electronic records of SAREL, Israel’s largest private supplier of drugs to healthcare and medical facilities. The data
were converted to defined daily doses (DDD) per 1000 inpatients per day.
Results: Usage of the ten atypical antipsychotic agents allocated through Israel’s national health care system increased by
73 %, from 128.09 DDD/1000 inpatients/day in 2004 to 221.69 DDD/1000 inpatients/day in 2013. This rise from 2004 to
2013 was largely due to a 1.6-fold increase in the administration of olanzapine (48.31 to 79.57 DDD/1000 inpatients/day),
a 4.4-fold increase of quetiapine (9.74 to 43.04 DDD/1000 inpatients/day) and 3.7-fold increase of amisulpride (5.54 to
20.38 DDD/1000 inpatients/day). At the same period, the total utilization of 12 main typical antipsychotics decreased by
15.5 %, from 148.67 DDD/1000 inpatients/day in 2004 to 125.57 DDD/1000 inpatients/day in 2013. Over the entire period,
total DDDs of both classes of antipsychotics (typical and atypical) increased by 38 %.
Conclusions: Similar to trends in the treatment of psychiatric outpatients in other countries, there was a substantial
increase in the administration of atypical antipsychotic drugs to the Israeli psychiatric inpatient population across the
study period. A decrease in the use of typical antipsychotics (substitution), polypharmacy, administration for more
indications (supplementation) and the use of larger doses of antipsychotics may account, in part, for this increase. The
findings have implications for mental health policy in the context of the Mental Health Care System Reform. Systematic
studies on appropriate dosing of antipsychotics and augmentation strategies are warranted.
Keywords: Atypical antipsychotics, Typical antipsychotics, Sertindole, Ziprasidone, Clozapine, Olanzapine, Quetiapine,
Amisulpride, Risperidone, Aripiprazole, Paliperidone, Iloperidone, Pharmacoepidemiology
Background
Serious mental illnesses (SMI), such as schizophrenia, schi-
zoaffective and bipolar disorders, are chronic medical disor-
ders with unknown etiology, complex pathophysiology and
polymorphic symptomatology. Mental, emotional and be-
havioral manifestations of the disorders result in serious
functional impairment, substantially interfering with or lim-
iting one or more major life activities and in turn decreas-
ing quality of life of the patients. Until the mid-1990s only
conventional antipsychotic drugs (typicals or first-
generation antipsychotics) were used to treat SMI. Atypical
antipsychotics (atypicals or second-generation antipsy-
chotics) are currently the first-line treatments for schizo-
phrenia [1, 2] and the recommended maintenance option
for bipolar disorder [3, 4]. Both typical and atypical anti-
psychotic agents block brain dopamine receptors and have
comparable efficacy, but atypicals have a safer profile of
neurological side-effects: they are less likely to cause extra-
pyramidal symptoms and tardive dyskinesia [5]. However,
atypicals may cause serious metabolic side-effects such as
significant weight gain, dyslipidemia and sometimes dia-
betes mellitus [6].
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Since their introduction in the mid-1990s, there has been
a proliferation of atypical antipsychotics and there are cur-
rently at least 15 atypicals available in psychiatric practice
in developed countries [7, 8]. According to the ATC classifi-
cation index [9], atypicals belong to four chemical groups:
1) indole derivatives (N05AE): sertindole and ziprasidone;
2) diazepines, oxazepines, and thiazepines (N05AH): cloza-
pine, olanzapine, and quetiapine; 3) benzamides (N05AL):
amisulpride, and 4) other antipsychotics (N05AX): aripipra-
zole, iloperidone, paliperidone and risperidone. The intro-
duction of each new atypical antipsychotic agent was
accompanied by intense debates among clinicians and re-
searchers regarding the efficacy, side-effect profiles and cost
efficiency of the various new drugs [7]. Head-to-head com-
parisons of atypical antipsychotics lead to the conclusion
that atypicals are not a homogenous class [7, 8]. Prescrip-
tion patterns and, consequently, administration rates of
these medications are most likely related to differences in
the properties of the atypicals. Clinicians’ prescribing pref-
erences also take into account cost, healthcare policies,
marketing, public perceptions, etc.
Over the past decade, several pharmacoepidemiological
studies exploring trends in prescription and administration
of psychotropic drugs (including atypical antipsychotics)
were conducted in different countries [10–13]. Trends were
reported for special (e.g., children) and non-institutionalized
(ambulatory) populations and were explained either by es-
calating off-label use or regulatory approval for indications
other than schizophrenia and related psychoses [14], such
as bipolar mania and depression [15], control of aggression,
ADHD and conduct disorders in children [16] and behav-
ioral problems in elderly patients with dementia [17]. In
addition, there are a few studies that assessed antipsychotic
drug use in inpatient settings [18, 19]. Findings revealed
that although the use of atypical antipsychotics dominated
inpatient practice, total antipsychotic dosing had not in-
creased from 1998 to 2002 [18]. In ambulatory settings,
from 2004 to 2009 total antipsychotic doses increased by
97 %, with better clinical improvement and without appar-
ent increase in major side-effects [19]. Unfortunately, an
analogous investigation was not carried out in Israel. Our
choice of the targeted population was based on both the
availability and reliability of the data on the use of atypicals
by psychiatric inpatients and the availability of reliable sta-
tistics of psychiatric admissions over the study period.
The psychiatric hospitalization system in Israel includes
ten psychiatric hospitals and twelve psychiatric wards in
general hospitals. These services provide inpatient care or
day hospitalization according to the severity of the pa-
tient’s condition. Despite major reform in the patterns of
mental health care which resulted in a massive reduction
in the number of inpatient beds - from 0.79/1000 popula-
tion in 2004 to 0.42/1000 population in 2013, the numbers
of persons hospitalized yearly over this period declined by
only 2.9 % from 18,286 in 2004 to 17,736 in 2013 [20].
Health insurance in Israel is mandatory and is provided
by major health maintenance organizations. The drugs
covered by the mandatory insurance are included in the
National List of Health Services (NLHS). All anti-
psychotic agents recommended as first-line treatment
(except for sertindole) for SMI, are included in the
health service list of approved medications. Findings from
this study could have important implications for mental
health policymakers and cross-country comparisons.
The primary aim of this study was to detect trends in the
use of typical antipsychotics (perphenazine, thioridazine,
clotiapine levomepromazine, fluphenazine, propericiazine,
chlorpromazine, haloperidol, flupentixol, zuclopenthixol,
pimozide, and sulpiride) and atypical antipsychotics (sertin-
dole, ziprasidone, clozapine, olanzapine, quetiapine, amisul-
pride, risperidone, aripiprazole, paliperidone and iloperidone)
in the Israeli inpatient psychiatric population throughout the
last decade. The second aim was to assess the possible con-
tributors to the trends in the use of antipsychotics. Namely,
if there is an increase in use of atypicals, does this occur en-
tirely at the expense of typicals (substitution), or does the
introduction of atypicals actually expand the total use of anti-
psychotics (supplementation)? The latter could occur if psy-
chiatrists are willing to use atypicals for patients or
indications where they were reluctant to use typicals.
Methods
Drug utilization data were derived from the database
maintained by SAREL which is the largest private sup-
plier of drugs to health maintenance organizations and
medical facilities in Israel. The company is the only pro-
vider of all atypical antipsychotic formulations (allocated
by the National Health Insurance system) to all psychiatric
hospitals and psychiatric departments in general hospitals
in Israel. Data on the total annual administration of the
medications (amisulpride, clozapine, olanzapine, quetia-
pine, risperidone, and ziprasidone) were evaluated for the
years 2004–2013. In addition, we analyzed consumption
of four other atypicals – sertindole, paliperidone, aripipra-
zole, and iloperidone that have been marketed in Israel
since 2008, 2009, 2011 and 2013, respectively. In parallel
to the analysis of the trends in total administration of
atypical antipsychotics, we also analyzed the changes in
typical antipsychotics over the same period. Dosages for
all drugs were converted to defined daily doses (DDD) per
1000 psychiatric inpatients per day, which is the average
maintenance dosage as defined by the World Health
Organization Collaborating Center for Drug Statistics
[21]. DDDs are based on the ATC classification index. [9]
To calculate administration rates, we used the formula
“number of DDD per 1000 psychiatric inpatients per day
= number of packages dispensed × number of doses per
package × number of mg per dose × 1000 psychiatric
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inpatients/DDD in mg x number of psychiatric patients in
Israel for the year × 365 days”. Data regarding the total
population of psychiatric patients (both inpatients and
those in day hospitalization) for each year studied were
obtained from the corresponding administrative databases
maintained by the Department of Information and Evalu-
ation in the Ministry of Health [20, 22]. The retrospective
study did not require Institutional Review Board approval
because of the anonymous nature of the data used (with-
out patient ID codes) (Table 1 and Fig. 1).
Results
Over the study period, the total annual administration of
atypical antipsychotics allocated by Israel’s national
health care system increased by 73 %, from 128.09 in
2004 to 221.69 DDD/1000 inpatients/day in 2013. Table 1
and Fig. 1 show that the administration of olanzapine in-
creased by a factor of 1.6, from 48.31 in 2004 to 79.57
DDD/1000 inpatients/day in 2013. The corresponding
figures for quetiapine demonstrated a 4.4-fold increase,
from 9.74 DDD/1000 in 2004 to 43.04 DDD/1000 inpa-
tients/day in 2013 and for amisulpride a 3.7-fold in-
crease, from 5.54 in 2004 to 20.38 DDD/1000 inpatients/
day in 2013. During the same period, clozapine adminis-
tration increased by 15 %, whereas risperidone adminis-
tration decreased by 18 %. There was also a 3-fold
reduction in ziprasidone administration. For more re-
cently marketed drugs, there was nearly a 9-fold rise in
paliperidone administration, from 1.34 in 2009 to 11.98
DDD/1000 inpatients/day in 2013 and a 1.5-fold rise in
aripiprazole utilization, from 4.04 in 2011 to 5.90 DDD/
1000 inpatients/day in 2013 (Fig. 2).
As can be seen in Fig. 2, out of four ATC antipsychotic
groups (N05AE; N05AH; N05AL, and N05AX), drug ad-
ministration, as measured by DDD per 1000 inpatients
per day, rose substantially during the study period only
in the N05AH group, while in the N05AX group the ad-
ministration rate increased slightly and there was even
some decline in the remaining groups (Fig. 3).
Figure 3 depicts change in proportions of the ATC
groups of atypical antipsychotics consumed in Israel
over the study period. As can be seen, there is a substan-
tial trend towards increase in the proportions of atypical
preparations from the N05AH group including cloza-
pine, olanzapine and quetiapine (from 56.7 % in 2004 to
73.4 % in 2013) alongside reduction in the proportions
of atypicals from the N05AE group including sertindole
and ziprasidone (4.9 % and 1.3 %, respectively), and the
N05AL group including amisulpride (22 % and 9.2 %, re-
spectively). The proportions of atypicals from the
N05AX group (risperidone, aripiprazole, paliperidone
and iloperidone) remained unchanged (around 16 %)
during the study period (Tables 2 and 3).
We assessed the use of atypical antipsychotics against the
use of typical antipsychotics at the same time period. As
can be seen in Table 2, the total utilization of 12 main
typicals (perphenazine, thioridazine, clotiapine levomepro-
mazine, fluphenazine, propericiazine, chlorpromazine,
haloperidol, flupentixol, zuclopenthixol, pimozide, and sul-
piride) decreased by 15.5 %, from 148.67 DDD/1000 inpa-
tients/day in 2004 to 125.57 DDD/1000 inpatients/day in
2013. The corresponding figures for individual typicals were
for Flupentixol 67 %, Chlorpromazine 62 %, Sulpiride 29 %,
Zuclopenthixol 16.5 %, and Haloperidol 8 %. Only
Pimozide’s use rose by 8 times at that period, from 0.03
DDD/1000 inpatients/day in 2004 to 0.24 DDD/1000 inpa-
tients/day in 2013. However, its portion of total typical anti-
psychotic consumption was small. Table 3 shows that for
the study period the ratio of atypical to typical antipsy-
chotics usage (expressed in percentages) has changed sig-
nificantly in favor of atypical medications, from 46.3/53.7 %
in 2004 to 63.8/36.2 % in 2013.
Table 1 Consumption in defined daily dose per 1000 psychiatric inpatients per day of ten atypical antipsychotics covered by Israel’s
national health care system, 2004 - 2013
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Olanzapine 48.31 44.69 65.79 55.85 55.14 64.48 47.39 58.04 89.50 79.57
Clozapine 34.87 27.03 45.02 28.44 30.08 41.07 31.59 38.40 44.85 40.22
Quetiapine 9.74 17.01 21.60 20.73 24.90 32.04 28.63 28.71 45.97 43.04
Risperidone 21.61 26.86 26.37 33.99 23.35 25.16 19.52 19.86 23.02 17.79
Paliperidone 1.34 3.42 5.26 14.79 11.98
Aripiprazole 4.04 5.53 5.90
Iloperidone 0.03
Amisulpride 5.54 6.03 8.57 7.71 9.41 9.33 11.29 16.92 23.92 20.38
Ziprasidone 8.02 4.77 3.42 3.18 3.53 3.28 3.24 4.20 2.46 2.69
Sertindole 0.36 1.01 0.35 0.11 0.24 0.11
Total 128.1 126.4 170.8 149.9 146.8 177.7 145.4 175.5 250.3 221.7
The blanks correspond to the periods in which the drugs were not marketed
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Regarding the substitution/supplementation question,
it was found that over the entire period, total DDDs of
both classes of antipsychotics (typical and atypical) in-
creased by 38 %. This shows that in addition to the sub-
stitution that is already noted (i.e., the decline in
typicals’ share), there was also a supplementation which
expanded overall use of antipsychotics.
Discussion
We investigated the trends in the administration of both
typical and atypical antipsychotic drugs in the inpatient
population in Israel over the last decade. Results show a
substantial increase in the total administration of atypi-
cals, with olanzapine, quetiapine and amisulpride and,
recently, aripiprazole and paliperidone accounting for
the increase. The administration of older atypicals rose
only slightly (e.g., clozapine) or was even somewhat
reduced (e.g., risperidone). The growth of atypicals rep-
resents both substitution and supplementation, since
atypicals’ share increased but so did the overall use of
antipsychotics (increased by 38 %). It appears that there
was not only substitution of typicals by atypicals, but
also use of atypicals for patients or indications in which
psychiatrists were reluctant to use typicals.
Similar trends towards increase in the utilization of
atypicals have been reported in other countries [12]. For
instance, there was 217 % increase between 2000 and
2011 in Australia; [13] the proportion of prescriptions for
atypicals rose from 7 % to 96 % between 1996 and 2001 in
the United States [16] and from 0 % to 78 % between 1999
and 2005 in Spain [10]. However, unlike our study, the
trends were reported for special (e.g., children) and non-
institutionalized (ambulatory) populations. The rise in
atypicals can be explained by both patterns (substitution
Fig. 1 Consumption trends for ten atypical antipsychotics covered by Israel’s national health care system, 2004 – 2013
Fig. 2 Consumption trends in the ATC atypical antipsychotic drug groups (DDD)
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and supplementation) [10, 12, 16]. The pattern of supple-
mentation was reflected by either escalating off-label use
or regulatory approval for indications other than schizo-
phrenia and related psychoses [14], such as bipolar mania
and depression [15], for the control of aggression, ADHD
and conduct disorder in children [16] and behavioral
problems in elderly patients with dementia [17]. The
trends for the increased administration of atypicals to the
inpatient population in our study may be explained by
some of the above factors, although we focused only on
hospitalized patients rather than outpatients.
Comparative efficacy and tolerability of each individual
drug should be considered when explaining the more ex-
tensive use of certain atypicals. In this respect, a recent
multiple-treatment meta-analysis comparing RCTs of 15
antipsychotics [8] provides evidence-based hierarchies
for the drugs. According to that analysis, clozapine is sig-
nificantly more effective than all the other antipsychotics,
followed by amisulpride, olanzapine and paliperidone.
Clozapine was found to produce fewer extrapyramidal
side-effects than all other drugs followed by sertindole,
olanzapine and quetiapine, whereas risperidone and
Fig. 3 Relative consumption trends across the ATC atypical antipsychotic drug groups
Table 2 Consumption of typical antipsychotics covered by Israel’s national health care system, 2004 – 2013 (defined daily dose per
1000 psychiatric inpatients per day)
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Perphenazine 1.39 1.55 2.04 2.23 2.39 2.38 1.90 2.57 2.64 2.55
Thioridazine 0.42 0.44 0.27 0.32 0.32 0.31 0.28 0.16 0.15 0.18
Clothiapine 6.37 5.27 8.37 5.83 6.59 5.58 6.66 6.64 5.37 4.63
Levomepromazine 0.77 0.95 0.84 0.7 1.19 0.61 0.82 0.77 0.79 1.05
Fluphenazine 70.25 61.17 58.92 57.69 56.86 58.00 54.74 65.53 56.78 57.56
Propericiazine(Periciazine) 0.12 0.14 0.12 0.18 0.22 0.16 0.15 0.13 0.18 0.17
Chlorpromazine 4.00 4.41 3.90 3.31 4.02 3.65 3.69 3.40 3.05 1.52
Haloperidol 42.37 42.31 37.64 45.34 45.75 47.32 45.83 49.04 40.63 38.95
Flupentixol 0.45 0.32 0.25 0.26 0.28 0.18 1.76 0.29 0.11 0.15
Zuclopenthixol 21.05 14.26 16.26 18.79 18.83 19.09 17.59 19.21 17.94 17.58
Pimozide 0.03 0.01 0.07 0.15 0.13 0.12 0.12 0.12 0.01 0.24
Sulpiride 1.40 1.56 2.59 1.58 1.53 1.59 1.10 1.03 1.16 0.99
Total 148.62 132.39 131.27 136.38 138.11 138.99 134.64 148.89 128.81 125.57
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paliperidone were among the less tolerated drugs. Hence,
the higher administration rates for olanzapine, quetiapine
and clozapine in our study could be explained by better
efficacy and tolerability. However, olanzapine and cloza-
pine induce significantly more weight gain than most
other antipsychotics, and iloperidone, sertindole, quetia-
pine, risperidone and paliperidone are associated with sig-
nificantly more weight gain than aripiprazole, amisulpride
and ziprazidone. In addition, there are mixed results for
the sedative effect that was found to be the highest for clo-
zapine, but low for both amisulpride and paliperidone.
Therefore, all-cause discontinuation, which encompasses
both efficacy and tolerability, is a more suitable measure
of drug acceptability and utility. From this perspective, the
significantly lower rates of all-cause discontinuation for
olanzapine, quetiapine and clozapine compared to other
atypicals [8] could account for their increasing consump-
tion. This explanation is supported by RCTs demonstrating
that patients with schizophrenia discontinue antipsychotics
mainly due to inefficacy rather than side effects, i.e.,
patients prioritize efficacy over tolerability [23].
Apart from the above explanations, our findings could
be accounted for by the fact that clinicians tend to in-
crease dosing of medications in an attempt to achieve a
better response. Prescription of high doses of antipsy-
chotics is common in hospitalized patients, despite the
lack of evidence for such an approach [24]. For example,
olanzapine and quetiapine are well tolerated at high
doses, and these doses may also produce greater im-
provement [25, 26], whereas increasing the dose of ris-
peridone beyond the optimal recommended dose range
(4–8 mg/day) does not improve effectiveness, but ex-
poses the patients to higher rates of side effects [27]. It
is possible that our observation of increased administra-
tion trends for olanzapine and quetiapine and decreased
utilization of risperidone reflect the changes in clinical
practice with regard to antipsychotic dosages owing to
clinicians’ greater awareness of the balance between clin-
ical benefit and emergent side effects [28].
Another possible explanation for the revealed trends
lays in the popular practice among clinicians of adminis-
tering more than one atypical to enhance treatment effect-
iveness (polypharmacy). The practice of polypharmacy in
the treatment of psychoses is common across countries
and clinical settings: [29], 28 % to 57 % of people with
schizophrenia reported using more than one antipsychotic
during a one-year follow-up [30, 31]. More specifically,
Novick and colleagues [32] reported that only 66.8 % of
patients treated with olanzapine, 52.6 % treated with ami-
sulpride and 43.4 % treated with quetiapine maintained
their baseline monotherapy over 12 months. Thus, poly-
pharmacy of large doses of several antipsychotics may be
partly responsible for the increased utilization trends in
Israel, at least for antipsychotics. Hence, systematic studies
on appropriate dosing of antipsychotics in conjunction
with augmentation strategies are warranted.
Health policy-related factors may also explain the ob-
served trends. As mentioned, all atypical antipsychotic
agents, except sertindole, are included in the Israeli list
of approved medications that are provided at no cost to
patients by the mandatory health insurance funds. The
inclusion of any pharmaceutical product in the drug list
is accompanied by approved indications and limitations
detailed in the National Health Insurance Law. Unfortu-
nately, the process of approval of the atypical antipsy-
chotics was made mainly at a bureaucratic level and
without the input of an expert committee and thus was
not clinical in nature. From 2004 throughout 2013, the
clinical indications for dispensation of atypical antipsy-
chotics were extended by the “health basket” committee
in the Ministry of Health. Thus, atypical antipsychotics
were granted priority over other treatment options (typical
antipsychotics) encouraging the use of atypicals, and con-
sequently, increasing their rates of administration. This
was true for olanzapine, quetiapine and amisulpride which
were approved in 2006 as first-line treatment for both
schizophrenia and bipolar disorder. Similarly, the adminis-
tration of paliperidone and aripiprazole rose following
their inclusion in the approved drug list in 2009 and 2010,
respectively.
Atypical (second-generation) antipsychotics were intro-
duced in Israel in 2000 and their cost was substantially
higher than that of first-generation antipsychotics. Re-
stricted use of atypicals reflected the significant budget
constraints of psychiatric hospitals. Despite the burden,
clinical reality required the use of atypicals to attenuate
the exposure to serious adverse effects (mainly extrapyr-
amidal) of the first-generation antipsychotics. However, it
Table 3 The relationship (%) between DDD of typical and atypical antipsychotics covered by Israel’s national health care system,
2004 – 2013 (defined daily dose per 1000 psychiatric inpatients per day)
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Typicals DDD total 148.62 132.39 131.27 136.38 138.11 138.99 134.64 148.89 128.81 125.57
Percent 53.7 51.2 43.5 47.6 48.5 43.9 48.1 45.9 34.0 36.2
Atypicals DDD total 128.1 126.4 170.8 149.9 146.8 177.7 145.4 175.5 250.3 221.7
Percent 46.3 48.8 56.5 52.4 51.5 56.1 51.9 54.1 66.0 63.8
All 276.72 258.79 302.07 286.28 284.91 316.69 280.04 324.39 379.11 347.27
Ponizovsky et al. Israel Journal of Health Policy Research  (2016) 5:16 Page 6 of 9
is of note that treatment with atypical antipsychotics is as-
sociated with obesity, diabetes and metabolic syndrome.
The medical care system’s cost of reducing EPS by going
over to second generation atypical antipsychotics in terms
of metabolic abnormalities should be investigated in fu-
ture studies. It is possible that the results of such studies
could reveal a historic mistake made in psychiatry.
It should be noted that the initial high costs of all new
atypical antipsychotics substantially decreased five years
following approval, which coincided with the introduc-
tion of their generic counterparts. Thus, the increase in
administration of atypicals can be attributed in part to
the registration of less expensive generic drugs in Israel.
The introduction of generic olanzapine in 2011 most
likely accounted for the sharp increase in its administra-
tion owing to the reduced cost.
The trends in the use of atypical antipsychotics re-
ported in this study provide useful information for policy
development for the treatment of patients with SMI, pa-
tients resistant to conventional treatment or those ex-
periencing serious adverse effects.
Policy implications for the near future
The National Health Insurance Law, introduced in Israel
in 1995, exposed a gap between provision of physical
and mental health services. Article 2 of the Law assigned
responsibility to the Health Maintenance Organizations
(HMOs) for physical health services. However, according
to Article 3, the State remained responsible for mental
health services. The Mental Health Service System Re-
form [33] declared that the State would finance psychi-
atric hospitals until July 2015, after which financial
responsibility would be transferred to the HMOs. Psy-
chiatric hospital budgets include salaries for staff (based
on collective agreements) and for all hospital operations,
including medications.
Given the above considerations, the Israeli Ministry of
Health allocated an earmarked 10 million NIS annual
budget for atypical antipsychotic agents. Over the last
decade, the number of new atypical antipsychotics in-
creased and their costs decreased following the introduc-
tion of generic forms of some of the atypicals. These
parallel processes allowed the psychiatric hospitals to ex-
tend the use antipsychotics and remain within the con-
straints of the existing budget.
The Mental Health Reform implemented fundamental
changes in the economic status of state psychiatric hos-
pitals: HMOs now finance all psychiatric hospitaliza-
tions, and the former state-owned hospitals no longer
receive government funding. Prior to the Mental Health
Reform, psychiatric hospitals received an earmarked
budget for atypical antipsychotics (approximately 14.5
million NIS total, or 2400 NIS per bed). Following im-
plementation of the reform, this special budget was
cancelled and the allotment was added to the cost per
day of hospitalization. Considering that most of the drug
company profits are from medications administered in
ambulatory care, negotiations are under way with the
pharmaceutical companies to reduce the cost of in-
patient medications. Economic limitations and inevitable
budget deficits will undoubtedly impact the choice of in-
patient antipsychotic treatment.
The use of clozapine will be extended for both acute and
chronic resistant patients for two reasons. First, clozapine is
the most effective treatment for schizophrenia patients who
are resistant to other atypicals, and second, its generic form
is relatively inexpensive. It is therefore expected that the
HMO’s will encourage psychiatric hospitals to initiate the
treatment with clozapine as early as possible, an advanta-
geous scenario for schizophrenia patients and their families.
Long-acting forms of atypical antipsychotics will be
prescribed mainly in community health-care settings as
maintenance treatment for schizophrenia and will be
prescribed in hospitals just prior to discharge in line
with HMO policy.
In sum, the trends detected in this study support sev-
eral recommendations for policy development regarding
the treatment of patients with SMI, patients resistant to
conventional treatment or those experiencing serious ad-
verse effects of conventional treatment.
Study limitations
The calculation of the defined daily dose (DDD) adjusts
total consumption of atypical antipsychotic medications
by the number of psychiatric inpatients nationwide.
Hence, variation in DDDs over time could reflect changes
in the volume of inpatients with disorders other than
schizophrenia, many of whom are less likely to be treated
with atypical antipsychotics. This could account for the
large year-to-year swings in DDDs, if the total psychiatric
inpatient population varies more over time than the size
of the inpatient population with schizophrenia.
In addition, our study included only inpatients in all
psychiatric settings (i.e., the most severe cases), hence
the obtained results cannot be generalized to outpatients
with SMI or the general population. As previously men-
tioned, this study sample was chosen because of the
availability of reliable data on atypical antipsychotic
utilization in the inpatient population and the reliable
statistics of psychiatric hospitalizations. Future studies
targeting outpatient populations are warranted.
Another limitation is the use of an aggregate, non-patient
level of data. Due to this limitation the contribution of
growth in polypharmacy, increasing doses over time, or in-
clusion of more patients receiving such treatments could
not be assessed. Furthermore, the aggregate data evaluation
cannot scrutinize explanations for changes in the prescrib-
ing patterns of atypical antipsychotic agents. Some of the
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factors that drive drug-specific prescribing trends are not
observable in aggregate data. As a result, a further study
could focus on explanatory factors that can be related to
the aggregate data, such as the timing of introduction of
various drugs to the market, and the dates that they were
first introduced as generics. A timeline with those changes
could add considerable value to the study by illustrating
which regulatory changes relate to which trends. Unfortu-
nately, we do not have reliable information regarding the
timing of drug and generic entry. The use of patient-level
data is an interesting topic for future study, in which the
number of patients using each medication could be
analyzed.
Finally, the time-frame for the trends of recently mar-
keted atypicals (paliperidone, iloperidone, and sertin-
dole) is shorter than for the older atypicals, such as
clozapine, olanzapine and risperidone. Further research
is needed to explore the consumption trends for the
novel atypicals in the long-term.
It appears that the growth in the use of atypicals rep-
resents both substitution for typicals as well as a supple-
mentation (expansion of the total use of antipsychotics),
namely, use of atypicals for patients or indications where
they were reluctant to use typicals. A 10-year retrospect-
ive study on the trends in prescribing psychotropic drugs
to children and adolescents within an inpatients adoles-
cent psychiatric ward in Israel has demonstrated that
typical antipsychotic prescriptions decreased by 35.5 %
while the prescriptions of atypical antipsychotics in-
creased by 51.5 % [34]. Similar analysis of the trends in
the types of antipsychotic prescribed to schizophrenia
patients over a 3-year period has been found in two
large mental health catchment areas of Auckland
(Australia): with an 18.6 % increase in atypical antipsy-
chotics and a 23.3 % decrease in both intramuscular and
oral typical antipsychotics [35].
Conclusion
The reasons for the increasing administration of atypical
antipsychotics, as well as the decrease in the consump-
tion of typicals, in the psychiatric inpatient population
over the last decade are not totally clear. Similar trends
have also been observed in other countries among psy-
chiatric outpatients. These trends seem to be related to
both substitution and supplementation. In the absence
of evidence on the nature of the increasing trends in the
utilization of atypical antipsychotics among inpatients,
the possible contribution of their extended off-label pre-
scription or potential augmentation strategies of combi-
nations of several antipsychotics (polypharmacy) cannot
be ruled out. Rigorous detailed research in dosing of an-
tipsychotics and their combined use is needed before
firm conclusions for solid policy changes can be drawn.
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